PT  - JOURNAL ARTICLE
AU  - Agarwal, Anup
AU  - Mukherjee, Aparna
AU  - Kumar, Gunjan
AU  - Chatterjee, Pranab
AU  - Bhatnagar, Tarun
AU  - Malhotra, Pankaj
AU  - Latha, B
AU  - Bundas, Sunita
AU  - Kumar, Vivek
AU  - Dosi, Ravi
AU  - Khambholja, Janak Kumar
AU  - de Souza, Rosemarie
AU  - Mesipogu, Raja Rao
AU  - Srivastava, Saurabh
AU  - Dube, Simmi
AU  - Chaudhary, Kiran
AU  - S, Subash
AU  - Mattuvar K, S. Anbuselvi
AU  - Rajendran, V
AU  - Sundararajaperumal, A
AU  - Balamanikandan, P
AU  - Maheswari, R S Uma
AU  - Jayanthi, R
AU  - Ragunanthanan, S
AU  - Bhandari, Sudhir
AU  - Singh, Ajeet
AU  - Pal, Ashok
AU  - Handa, Anjali
AU  - Rankawat, Govind
AU  - Kargirwar, Ketan
AU  - Regi, Joyce
AU  - Rathod, Darshana
AU  - Pathrose, Edwin
AU  - Bhutaka, Nirankar
AU  - Patel, Mayur H
AU  - Verma, Rahul J
AU  - Malukani, Kamal
AU  - Patel, Shivani
AU  - Thakur, Apurv
AU  - Joshi, Satish
AU  - Kulkarni, Rashmi
AU  - Suthar, Nilay N
AU  - Shah, Nehal M
AU  - Purohit, Hemang M
AU  - Shah, Cherry K
AU  - Patel, Monila N
AU  - Shah, Saket
AU  - Shah, Smit H
AU  - Memon, Tehsim
AU  - Beriwala, Vishal R
AU  - Jashnani, Kusum
AU  - Ezzy, Fatema
AU  - Agrawal, Simran
AU  - Bhadade, Rakesh
AU  - N, Atish M
AU  - Madke, Tushar
AU  - Kavishwar, Vikash
AU  - Waghmare, Ramesh
AU  - Valvi, Nitin
AU  - Chander, B Thrilok
AU  - Sekhar, A Vinaya
AU  - Maurya, Akhilesh Kumar
AU  - Hemanth, K
AU  - Nagamani, K
AU  - Sudha, K
AU  - Chandra, T Ravi
AU  - Rao, K Tushara
AU  - Vyshnavi, J
AU  - Upadhyay, Rashmi
AU  - Bahadur, Shalini
AU  - Pathak, Rambha
AU  - Seth, Shikha
AU  - Gupta, Rakesh
AU  - Saxena, Rita
AU  - Dwivedi, Preksha
AU  - Malik, Reeni
AU  - Chourasia, Deepti
AU  - Lalwani, Jaya
AU  - Sharma, UM
AU  - Marko, JL
AU  - Suri, Amit
AU  - Kumar, Vijay
AU  - Kaushik, Rajnish
AU  - Kodan, Parul
AU  - Acharya, Bhabani Prasad
AU  - Gaur, Kuldeep Kumar
AU  - Gupta, Anubhav
AU  - Sachdeva, Prerna
AU  - Dogra, Shruti
AU  - Jindal, Aikaj
AU  - John, M Joseph
AU  - Dhanju, Avtar Singh
AU  - Khetrepal, Ranjana
AU  - Sharma, Neeraj
AU  - Kukar, Neetu
AU  - Kavita, Divya
AU  - Kumar, Rajesh
AU  - Mahajan, Rajesh
AU  - Singh, Gurpreet
AU  - Kaur, Jaspreet
AU  - Singh, Raminder Pal
AU  - Bassi, Rajni
AU  - Parikh, Swapneil
AU  - Shrivastav, Om
AU  - Shastri, Jayanthi
AU  - Desai, Maherra
AU  - Udupa, Shreevatsa
AU  - Bafna, Varun A
AU  - Barge, Vijay
AU  - Madane, Rajendra
AU  - Yadav, Sheetal
AU  - Mishra, Sanjeev
AU  - Bajpayee, Archana
AU  - Garg, M K
AU  - Bohra, G K
AU  - Nag, Vijaylakshmi
AU  - Anne, Puneeth Babu
AU  - Nadeem, Mohd
AU  - Singh, Pallavi
AU  - Niwas, Ram
AU  - Khaire, Niranjan Shiwaji
AU  - Sharma, Rattiram
AU  - Singh, Mini p
AU  - Sachdeva, Naresh
AU  - Sachdev, Suchet
AU  - Hans, Rekha
AU  - Suri, Vikas
AU  - Yaddanapudi, L N
AU  - Lakshmi, PVM
AU  - Singh, Neha
AU  - Bhushan, Divendu
AU  - Kumar, Neeraj
AU  - Tambe, Muralidhar
AU  - Salvi, Sonali
AU  - Kadgi, Nalini
AU  - Sangle, Shashikala
AU  - Nakate, Leena
AU  - Joshi, Samir
AU  - Karyakarte, Rajesh
AU  - Goyanka, Suraj
AU  - Sharma, Nimisha
AU  - Verma, Nikhil
AU  - Das, Asim
AU  - Bahl, Monika
AU  - Wadhwa, Nitya
AU  - Bhat, Shreepad
AU  - Deshmukh, Shweta
AU  - Wagh, Vrushali
AU  - Kulkarni, Atul
AU  - Yardi, Tanvi
AU  - Kalgud, Ram S
AU  - Reddy, Purushottam
AU  - Yevoor, Kavitha
AU  - Gajula, Prashanth
AU  - Maleyur, Vivek
AU  - S, Medini
AU  - HN, Mohith
AU  - Gurtoo, Anil
AU  - Sud, Ritika
AU  - Pahuja, Sangeeta
AU  - Prakash, Anupam
AU  - Gogoi, Parijat
AU  - Shukla, Shailja
AU  - Reddy, D Himanshu
AU  - Chandra, Tulika
AU  - Pandey, Saurabh
AU  - Maurya, Pradeep
AU  - Wahid, Ali
AU  - Kumar, Vivek
AU  - Upadhyay, Kamlesh
AU  - Bhatnagar, Nidhi
AU  - Shah, Nilima
AU  - Shah, Mamta
AU  - Patel, Tarak
AU  - Jaiswal, Ram Mohan
AU  - Jain, Ashish
AU  - Sharma, Shweta
AU  - Rijhwani, Puneet
AU  - Gupta, Naveen
AU  - Patel, Tinkal C
AU  - Solu, Mahesh G
AU  - Patel, Jitendra
AU  - Shah, Yash R
AU  - Jarag, Mayur
AU  - Godbole, Varsha
AU  - Shah, Meenakshi
AU  - Raj, Rikin
AU  - Nagori, Irfan
AU  - Jha, Pramod R
AU  - Shah, Arti D
AU  - Yeeli, Gowtham
AU  - Jain, Archit
AU  - Gill, Rooppreet Kaur
AU  - Babu, KV Sreedhar
AU  - Babu, B Suresh
AU  - Mohan, Alladi
AU  - Vengamma, B
AU  - Sekhar, K Chandra
AU  - Damam, Srinivasulu
AU  - Narsimhulu, K
AU  - Aparna, C
AU  - Baleswari, G
AU  - K, Ravindranath Reddy
AU  - Chandrasekhar, P
AU  - Panjwani, Sunil Jodharam
AU  - Akholkar, Pankaj J
AU  - Joshi, Kairavi Parthesh
AU  - Shah, Pragnesh H
AU  - Barvaliya, Manish
AU  - Baldi, Milind
AU  - Yadav, Ashok
AU  - Gupta, Manoj
AU  - Rawat, Nitin
AU  - Chawda, Dilip
AU  - Natarajan, M
AU  - Sintha, M
AU  - Kumar, David Pradeep
AU  - Rabbani, Fathhur
AU  - Khadke, Vrushali Khirid
AU  - Patki, Dattatray
AU  - Marathe, Sonali
AU  - D Souza, Clyde
AU  - Tadha, Vipul
AU  - Arora, Satyam
AU  - Gupta, Devendra Kumar
AU  - Dua, Seema
AU  - Chauhan, Nitu
AU  - Chahar, Ajeet Singh
AU  - Mammen, Joy John
AU  - Kumar, Snehil
AU  - Daniel, Dolly
AU  - Singh, Ravindraa
AU  - Dhat, Venkatesh
AU  - Agarwal, Yogesh
AU  - Arora, Sohini
AU  - Pathak, Ashish
AU  - Purohit, Manju
AU  - Sharma, Ashish
AU  - Sharma, Jayashree
AU  - Madkaikar, Manisha
AU  - Joshi, Kavita
AU  - Yadav, Reetika Malik
AU  - Bhagwat, Swarupa
AU  - Karnik, Niteen D
AU  - Gokhale, Yojana A
AU  - Naik, Leena
AU  - Margam, Sangita
AU  - Das, Santasabuj
AU  - Turuk, Alka
AU  - Kumar, V Saravana
AU  - Kanagasabai, K
AU  - Sabarinathan, R
AU  - Deshpande, Gururaj
AU  - Sharma, Sharda
AU  - Gunjikar, Rashmi
AU  - Shete, Anita
AU  - Phagiwala, Darpan
AU  - Patil, Chetan
AU  - Shingade, Snehal
AU  - Jarande, Kajal
AU  - Kaushal, Himanshu
AU  - Yadav, Pragya
AU  - Sapkal, Gajanan
AU  - Abraham, Priya
TI  - Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)
AID  - 10.1101/2020.09.03.20187252
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.03.20187252
4099  - http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.short
4100  - http://medrxiv.org/content/early/2020/09/10/2020.09.03.20187252.full
AB  - Objectives: Convalescent plasma (CP) as a passive source of neutralizing antibodies and immunomodulators is a century-old therapeutic option used for the management of viral diseases. We investigated its effectiveness for the treatment of COVID-19. Design: Open-label, parallel-arm, phase II, multicentre, randomized controlled trial. Setting: Thirty-nine public and private hospitals across India. Participants: Hospitalized, moderately ill confirmed COVID-19 patients (PaO2/FiO2: 200-300 or respiratory rate > 24/min and SpO2 ≤ 93% on room air). Intervention: Participants were randomized to either control (best standard of care (BSC)) or intervention (CP + BSC) arm. Two doses of 200 mL CP was transfused 24 hours apart in the intervention arm. Main Outcome Measure: Composite of progression to severe disease (PaO2/FiO2<100) or all-cause mortality at 28 days post-enrolment. Results: Between 22 nd April to 14 th July 2020, 464 participants were enrolled; 235 and 229 in intervention and control arm, respectively. Composite primary outcome was achieved in 44 (18.7%) participants in the intervention arm and 41 (17.9%) in the control arm [aOR: 1.09; 95% CI: 0.67, 1.77]. Mortality was documented in 34 (14.5%) and 31 (13.5%) participants in intervention and control arm, respectively [aOR) 1.06 95% CI: 0.61 to 1.83]. Interpretation: CP was not associated with reduction in mortality or progression to severe COVID-19. This trial has high generalizability and approximates real-life setting of CP therapy in settings with limited laboratory capacity. A priori measurement of neutralizing antibody titres in donors and participants may further clarify the role of CP in management of COVID-19.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare that TB is a member of the National Task Force for COVID-19 which approved the protocol. AM, AA, GK, AT, TB, VS, KK, RS, SD, GD, SS, RG, AS, DP, CP, SS, KJ, HK, PDY, GS, PA, MM, RMY are employed with ICMR, the funding source for the trial. PC was an employee of ICMR during the trial. The funding source (ICMR) has no financial interest in the investigational product. No other author has any competing financial or non-financial interest.Clinical TrialCTRI/2020/04/024775Funding StatementThis multi-centric study was funded by ICMR, an autonomous Government-funded medical research council. The National Task Force for COVID-19, a committee formed by ICMR to respond to the pandemic has reviewed and approved this study. The Central Implementation Team at ICMR was responsible for study design, study coordination, data analysis, data interpretation and writing of the report. Patient enrolment, data collection and actual conduct of the study was done at public and private hospitals independently and the investigators in ICMR had no role in it. The funding source has no financial interest in the investigational product. The corresponding author at ICMR had access to all the data, is the guarantor for the current work and holds final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics comittee at the Indian council Medical Research, India and Intitutional review boards of all participating institutes.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual patient level data, collected in connection with the PLACID Trial, along with a data dictionary defining the variable fields has been developed and is available with the corresponding author. De-identified participant level data with data dictionary, or a sub-set thereof, may be made available upon written request to the corresponding author. Additional documents, including the study protocol, statistical analysis plan have been made available as supplementary files within the original submission. Results of secondary or sub-group analyses will be provided on request. Data will be made available, upon request once the trial is published. Data requests should be accompanied by a brief proposal outlining the analysis plan, which may be carried out with investigator support. A signed data access agreement may be needed to ensure data safety and compliance with national rules regarding data sharing.